Dr. Murphy-Chutorian has served as a member of our board of directors since September 2012 and as our chief executive officer since late October 2012. Dr. Murphy-Chutorian has more than 30 years of broad, diverse experience in healthcare, spanning positions including clinician, academician, inventor, entrepreneur, chief executive officer, chairman of the board, and consultant to financial firms. Prior to joining Semler, from 2005 to 2012, he was managing director of Select Healthcare Capital, LLC. Dr. Murphy-Chutorian is a named inventor on more than 30 patents and has guided more than 50 products through various regulatory approval processes. His business career has included extensive involvement in all facets of the medical industry from financial, research and development, manufacturing and marketing and sales, to regulatory, reimbursement and clinical trials. His breadth of healthcare experience includes all major sectors of the industry: medical devices, health services, pharmaceuticals, biotechnology and managed care. He received his B.A. and M.D. from Columbia University. Dr. Murphy-Chutorian completed his internal medicine residency at New York University/Bellevue Medical Center and his fellowship in cardiology at Stanford University Medical Center. He has served as a faculty member in interventional cardiology at both Stanford and Montefiore Medical Center.
Mr. Conger has served as our vice president of finance since October 2010. He has been actively involved in the medical device, start-up and biotechnology industries since 2006, and has experience designing and implementing internal control systems, and running finance in a business centered manner.
Ms. Oliva Herrington joined Semler in October 2010. She currently serves as our chief revenue officer, overseeing our sales, technical and training operations, driving new strategies and launching and delivering new programs and products. She is a seasoned executive, expert at working within Medicare Advantage and Managed Care environments including health plans, IPAs, ACOs, MSOs and health risk assessment companies.
Mr. Kermode joined Semler in March 2015 and serves as our senior vice president of operations. In that capacity, he is responsible for leading numerous areas of the business including manufacturing, FDA and HIPPAA/HITECH/HITRUST compliance, new product introduction and intellectual property. He is a highly experienced med-tech executive with comprehensive expertise in managing the people and technologies required to bring innovative products to market.
Mr. Reid joined Semler in April 2019. As our senior vice president of technology, he leads our team of engineers and IT professionals who deliver clinical algorithms, mobile and desktop applications, hardware, healthcare system interconnects and cloud based services. He has wide-ranging experience as an engineer and manager, from the smallest scale start-up to large, multi-divisional organizations.
Ms. Guinasso joined Semler in October 2010. As senior vice president of business development, she is responsible for spearheading and executing our company’s business development plans, business model development, strategic partnerships and go-to market strategy and commercialization efforts. She is an experienced healthcare executive with extensive expertise in the healthcare services and med-tech industries.
Mr. Rosenberg has served as chief marketing officer since January 2013 and has over 28 years’ experience in medical device marketing with start-up companies through international public companies, including senior level marketing and sales positions with Covidien, Bacchus Vascular, VNUS Medical, Eclipse Surgical Technologies and others.
Ms. Cormier joined Semler in May 2022 as our head of corporate communications and business strategy. In this capacity, she leads our investor relations efforts, and is instrumental in helping to shape the overall strategic direction of the company. Ms. Cormier has extensive investing, finance and accounting experience and was most recently a partner at a buy side investment firm focusing on public equity securities.